These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 6498856)

  • 1. Continuous-infusion vinblastine for treatment of refractory epithelial carcinoma of the ovary: a phase II trial.
    Kavanagh JJ; Wharton JT; Rutledge FN
    Cancer Treat Rep; 1984 Nov; 68(11):1417-8. PubMed ID: 6498856
    [No Abstract]   [Full Text] [Related]  

  • 2. Intermittent Iv homoharringtonine for the treatment of refractory epithelial carcinoma of the ovary: a phase II trial.
    Kavanagh JJ; Gershenson DM; Copeland LJ; Wharton JT; Rutledge FN; Krakoff IH
    Cancer Treat Rep; 1984 Dec; 68(12):1503-4. PubMed ID: 6542450
    [No Abstract]   [Full Text] [Related]  

  • 3. Continuous-infusion spirogermanium for the treatment of refractory carcinoma of the ovary: a phase II trial.
    Kavanagh JJ; Saul PB; Copeland LJ; Gershenson DM; Krakoff IH
    Cancer Treat Rep; 1985 Jan; 69(1):139-40. PubMed ID: 3967257
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of vinblastine in advanced refractory ovarian carcinoma.
    Grosh WW; Brenner DE; Jones HW; Burnett LS; Greco FA
    Am J Clin Oncol; 1983 Oct; 6(5):571-5. PubMed ID: 6613922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of 5-day infusion of vinblastine in patients with advanced ovarian carcinoma.
    Shah MK; St Marie K; Catalano RB; Dierks K; Creech RH
    Cancer Treat Rep; 1985 Feb; 69(2):229-30. PubMed ID: 3882232
    [No Abstract]   [Full Text] [Related]  

  • 6. [Experimental local cytostatic therapy of vulvar carcinoma using vinblastine].
    Brandl K; Schneider W
    Krebsarzt; 1967; 22(6):385-90. PubMed ID: 5589245
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer.
    Burger RA; DiSaia PJ; Roberts JA; O'rourke M; Gershenson DM; Homesley HD; Lichtman SM; Barnes W; Moore DH; Monk BJ
    Gynecol Oncol; 1999 Feb; 72(2):148-53. PubMed ID: 10021293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of vinblastine in previously treated patients with ovarian cancer: a Southwest Oncology Group Study.
    Surwit EA; Alberts DS; O'Toole RV; Graham V; Hannigan EV; Stephens RL; Boutselis JG
    Gynecol Oncol; 1987 Jun; 27(2):214-9. PubMed ID: 3570059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
    Cowan JD; Surwit EA; Alberts DS; Boutselis JG; Neilan BA
    Cancer Treat Rep; 1986 Mar; 70(3):423-4. PubMed ID: 3955558
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy in the treatment of ovarian cancer.
    Limburg HG
    Proc R Soc Med; 1969 Apr; 62(4):361-2. PubMed ID: 4980488
    [No Abstract]   [Full Text] [Related]  

  • 12. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of spirogermanium in advanced epithelial carcinoma of the ovary.
    Weiselberg L; Budman DR; Schulman P; Vinciguerra V; Degnan TJ; Pasmantier M
    Cancer Treat Rep; 1982 Aug; 66(8):1675-6. PubMed ID: 7201885
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic trial of a combination of cytostatic agents in advanced ovarian carcinoma].
    Brandl K
    Zentralbl Gynakol; 1970 Feb; 92(8):233-9. PubMed ID: 5505972
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B; Hansen HH; Høgdall C; Engelholm SA
    Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I-II trial of a 5-day continuous infusion of vinblastine sulfate.
    Zeffren J; Yagoda A; Kelsen D; Winn R
    Anticancer Res; 1984; 4(6):411-3. PubMed ID: 6517534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.
    Emons G; Ortmann O; Teichert HM; Fassl H; Löhrs U; Kullander S; Kauppila A; Ayalon D; Schally A; Oberheuser F
    Cancer; 1996 Oct; 78(7):1452-60. PubMed ID: 8839551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
    Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.